Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Diagnology

This article was originally published in The Gray Sheet

Executive Summary

Ireland-based company files 510(k) with FDA for the Pockit HSV 2 rapid test, a point-of-care test for herpes simplex virus type 2. If cleared by FDA, the test would be the first that would allow physicians to identify HSV-2 at the point of care. Results are available in about 10 minutes, Diagnology states. The company, which has a U.S. unit in Walpole, Massachusetts, launched the test in Europe a year ago. The test is an immuno-based assay and can be used in physician offices with whole blood or serum in the lab

Latest Headlines
See All
UsernamePublicRestriction

Register

MT010921

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel